Abstract:Zerumbone (ZER), a potential anticancer agent for breast cancer treatment, has limited clinical applications due to its poor water solubility and targeting ability. The poor water solubility of ZER has been partly overcome by loading into nanostructured lipid carriers (ZER-NLC). However, the lack of targeting and selectivity is still a concern in clinical settings. To overcome these limitations, ZER-NLC was co-loaded with an active-targeting agent known as superparamagnetic iron oxide nanoparticles (SPION) that may direct ZER-NLC to the tumor site with an external magnetic field. This multi-modal therapeutic regime (ZER-SPION-NLC) was optimized using Box-Behnken design with good physicochemical properties, stability, and hemocompatibility. ZER-SPION-NLC was milky brownish in color with an average diameter of 140.32 ± 1.14 nm, polydispersity index of 0.18 ± 0.02, and zeta potential of −13.37 ± 0.61 mV. Transmission electron microscopy analysis confirmed the homogeneous, spherical, and uniform distribution of ZER-SPION-NLC. The release of ZER from the carrier followed zero-order kinetics and showed no significant differences in both acidic and physiological conditions, proving that the drug release was pH-independent. The ZER-SPION-NLC was cytotoxic against non-cancerous Vero. STAT1 cells, both MCF-7 and MDA-MB-231 breast cancer cell lines with half maximal inhibitory concentration values of 1.46 ± 0.33 μg/mL, 1.85 ± 0.15 μg/mL and 1.81 ± 0.16 μg/mL, respectively at 72 h of treatment. Interestingly, ZER-SPION-NLC showed a higher apoptotic effect towards MDA-MB-231 (29.63%) than MCF-7 cells (13.37%) at 48 h. This observation could be explained by the different half maximum uptake value (K m ) and internalization mechanisms of ZER-SPION-NLC in these two cell lines. The uptake of ZER-SPION-NLC in MDA-MB-231 was via an active energy-dependent process with a faster uptake rate (K m value = 6 min) while the uptake in MCF-7 cell line is slower (K m value = 25 min) via caveolae-mediated endocytosis. Under a 0.5 T magnetic field, the magnetic properties of SPION were sufficient to direct ZER-SPION-NLC, resulting in increased uptake by 40.41% in MDA-MB-231 cells and 19.35% in MCF-7 than non-magnetic targeted cells. In conclusion, ZER-SPION-NLC could be a potential magnetic guiding multi-modal therapeutic system for breast cancer treatment. Graphical abstract Download : Download high-res image (397KB) Download : Download full-size image

Zerumbone: A Potent Emerging Phytochemical with Anticancer Therapeutic Potential

Anti-cancer potential of zerumbone in cancer and glioma: current trends and future perspectives

[Advances on Anti-Tumor Mechanisms of Zerumbone].

Tumor-Inhibitory Effects of Zerumbone Against HT-29 Human Colorectal Cancer Cells

Zerumbone (ZER), a Potential Anticancer for Breast Mediates Cancer Cell Death Through Targeting β-catenin Signaling Pathway in MCF-7 Cell Line

Cellular and molecular antiproliferative effects in 2D monolayer and 3D-cultivated HT-29 cells treated with zerumbone

Zerumbone-incorporated liquid crystalline nanoparticles inhibit proliferation and migration of non-small-cell lung cancer in vitro

Zerumbone (ZER), a Potential Anticancer for Breast Mediates Cancer Cell Death Through Targeting β-catenin Signaling Pathway in Tumor Regression in Sprague Dawley Rat Mammary Gland Tumors

Phytometabolites as modulators of breast cancer: a comprehensive review of mechanistic insights

An Updated Insight into Phytomolecules and Novel Approaches used in the Management of Breast Cancer

ANTIANGIOGENIC ACTIVITY AND ROS-MEDIATED LUNG CANCER CELL LINE INJURY OF ZERUMBONE

Zerumbone Induces Apoptosis in Breast Cancer Cells by Targeting αvβ3 Integrin upon Co-Administration with TP5-iRGD Peptide

Harnessing the nutriceutics in early-stage breast cancer: mechanisms, combinational therapy, and drug delivery

Berberine as a Potential Anticancer Agent: A Comprehensive Review

Phytochemically Derived Zingerone Nanoparticles Inhibit Cell Proliferation, Invasion and Metastasis in Human Oral Squamous Cell Carcinoma

Phytoconstituent-derived zingerone nanoparticles disrupt the cell adhesion mechanism and suppress cell motility in melanoma B16F10 cells

Molecular Targets of Plant-based Alkaloids and Polyphenolics in Liver and Breast Cancer- An Insight into Anticancer Drug Development

Combating breast cancer using combination therapy with 3 phytochemicals: Piperine, sulforaphane, and thymoquinone

Magnetic-guided targeted delivery of zerumbone/SPION co-loaded in nanostructured lipid carrier into breast cancer cells

The potential role of dietary plant ingredients against mammary cancer: a comprehensive review

METABOLITES OF ABRUS PRECATORIUS TARGETING MULTIPLE ONCOGENIC AND ONCO-SUPPRESSIVE SIGNALING FOR CANCER PREVENTION AND INTERVENTION